In-body CAR T gene editing & Lab-grown oesophagus transplants - News (Mar 20, 2026)

A striking advance in gene editing: researchers say they’ve found a way to generate CAR T cells directly inside the body, with precise insertion at a well-known “control point” in human T cells called the TRAC locus. The headline isn’t just that CAR T cells can be made in vivo—it’s that the team reports targeted integration of a large DNA payload in primary human T cells inside living models, which could make these therapies more predictable and reduce risks that come with random DNA insertion or CAR activity in the wrong cell types. In humanized mice, they reached what they call therapeutic levels of edited T cells, saw strong anti-cancer effects across multiple tumor models, and did not observe systemic cytokine release in the setting they tested. It’s early, but it points toward a future where cell-therapy benefits might be delivered more like a medicine—faster, and potentially at much larger scale.

In the UK, researchers have grown fully functioning oesophaguses in the lab and transplanted them into Göttingen minipigs—restoring swallowing without the need for anti-rejection drugs. The work is aimed at children born with gaps in the oesophagus, a rare but devastating condition that often means repeated major surgeries and long-term complications. In the study, several animals recovered well over months, with grafts showing the kinds of muscle, nerves, and blood supply you’d want in real tissue. The team says a key goal is a safer, earlier-life fix that avoids a cycle of procedures and side effects, and they’re talking about a potential pathway to treating children within about five years—though this approach isn’t designed for adult-sized needs like cancer surgery.

From Singapore, a different kind of bioengineering: scientists built a “self-training” platform for lab-grown skeletal muscle, where two muscle tissues are mechanically linked so they effectively work out against each other all day as they mature. That matters because one of the big limits in muscle-powered devices has been weakness—cultured muscle often can’t generate enough force to be practical. They used the stronger tissue to drive a biohybrid swimming robot, and reported unusually fast performance for a muscle-driven machine, with improved control including start-and-stop triggers. Beyond the cool factor, the takeaway is more durable, stronger living actuators—something that could eventually support soft robots for environmental monitoring or temporary medical tools that don’t leave long-lived waste behind.

On HIV prevention in South Africa, the National Aids Council is pushing to expand access to lenacapavir, the twice-yearly injection registered in the country late last year. The new move: inviting local drug makers to apply to produce generic versions, with the aim of securing a voluntary licence and bringing production closer to home. The challenge is that manufacturing the active ingredient is complex, and previous attempts haven’t succeeded—but the stakes are high. Donor-funded starter supply won’t cover anywhere near national need, and with global health funding under pressure, domestic and regional manufacturing is increasingly seen as a cornerstone of long-term prevention plans.

Now to the Middle East, where the U.S.–Iran war is entering a more perilous decision zone. President Donald Trump is weighing whether to send U.S. ground troops into Iran to secure or destroy a large stockpile of enriched uranium—material that could potentially be used in a nuclear weapons program. Experts say that because the uranium is believed to be buried under rubble at struck sites, removing or confirming control of it may be difficult without a significant on-the-ground presence. Lawmakers from both parties are signaling they haven’t been clearly briefed on how the administration plans to square its stated goal—preventing Iran from ever getting nuclear weapons—with its desire to avoid an extended ground operation. And analysts warn there’s risk in both directions: sending troops could become politically and militarily costly, but leaving the uranium unsecured could fuel future escalation if hard-liners decide a weapon is the best deterrent.

Defense Secretary Pete Hegseth, meanwhile, says the U.S. is preparing its largest strike package yet, as the conflict spreads across energy and military infrastructure. After Israel hit Iran’s South Pars gas field and Iran retaliated across the region, Washington is signaling deeper operations and is reportedly seeking major additional funding from Congress. The broader implication is that even if leaders insist they want limited aims, the combination of infrastructure attacks, retaliation, and funding needs can pull a campaign into a larger, longer commitment. Separately, the FBI is investigating former National Counterterrorism Center Director Joe Kent over alleged classified-information leaks—another sign of domestic strain as the war intensifies.

That same conflict is now rippling into a less obvious but critical supply chain: helium. Iran’s attacks have disrupted operations at Qatar’s Ras Laffan Industrial City, a major global source of helium produced alongside LNG exports. Before the war, Qatar supplied more than a third of the world’s helium, and this disruption could hit semiconductor manufacturing and medical imaging first—industries that rely on consistent, high-purity supply. Spot prices have already surged, though many buyers are on longer-term contracts that may delay broader price resets. Chipmakers in South Korea and Taiwan look particularly exposed, and even prioritized customers may have to juggle intermittent supply until production is stable again.

In China, a viral AI tool called OpenClaw is being pushed into the mainstream at remarkable speed—helped along by public install events hosted by tech giants and local meetups that make adoption feel like a community project. The pitch from users is simple: the “agent” can take on routine computer tasks, which some say makes small teams—or even solo entrepreneurs—more viable by automating admin work. But the story has two sides. As usage spreads, authorities are also issuing sharper warnings about security and data exposure, and sensitive sectors are reportedly being told to limit it. It’s a familiar tension: rapid diffusion for productivity gains, followed by tighter guardrails once risks become harder to ignore.

Brazil has moved in a different direction on tech—tightening rules to protect minors online. A new Digital Statute of Children and Adolescents is now in effect, aiming to curb addictive design and exposure to violent or sexual content. Among the notable changes: under-16 accounts must be linked to a legal guardian, and platforms are restricted from using engagement features such as autoplay and endless scrolling for minors. The law gained momentum after a widely viewed video helped force the issue into the national spotlight. Supporters argue it shifts responsibility away from families alone and toward the companies shaping children’s online environments—while critics and experts alike say success will hinge on how well the rules are explained and enforced in real life.

And finally, a development in mental health research that could reshape how schizophrenia is studied and, eventually, treated. A Northwestern University team reports a newly identified biomarker in cerebrospinal fluid tied to cognitive symptoms—an area where current antipsychotic drugs often fall short. They found reduced levels of a soluble form of a brain protein, linked to overly excitable neural circuits, and tested a synthetic version of the molecule in a mouse model. In that experiment, a single injection normalized circuit activity and improved schizophrenia-like behavioral deficits without obvious sedation. The big significance here is the direction: moving psychiatry toward more objective biological signals, and potentially toward treatments matched to the patients most likely to benefit—though human testing and easier screening methods, like a blood-based test, still lie ahead.